<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327111432503</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327111432503</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Use of naloxone in the treatment of benzodiazepine poisoning</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yuan</surname>
<given-names>W</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111432503"/>
<xref ref-type="corresp" rid="corresp1-0960327111432503"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>BN</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111432503"/>
</contrib>
<aff id="aff1-0960327111432503">Family Behavioral Health, Department of Psychiatry, Forsyth Medical Center, Winston-Salem, NC, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0960327111432503">Weiqing Yuan, Family Behavioral Health, Department of Psychiatry, Forsyth Medical Center, 3333 Silas Creek Parkway, Winston-Salem, NC 27103, USA Email: <email>weiqingyuan@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>31</volume>
<issue>4</issue>
<fpage>406</fpage>
<lpage>407</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>We read with interest the recent article by Solhi et al.,<sup>
<xref ref-type="bibr" rid="bibr1-0960327111432503">1</xref>
</sup> studying the use of naloxone in benzodiazepine poisoning treatment and the comments by Jang et al.<sup>
<xref ref-type="bibr" rid="bibr2-0960327111432503">2</xref>
</sup> It is an interesting topic and we would like to express our thoughts on these comments and concerns based on the literature review.</p>
<p>Jang et al. had a concern: ‘Since naloxone is a known antidote for opioid toxicity, it is very important to exclude their presence to validate the data obtained’.<sup>
<xref ref-type="bibr" rid="bibr2-0960327111432503">2</xref>
</sup> This is a good point to make this article better. However, this might not affect the final conclusion in this study based on the results.</p>
<p>First, a number of studies show that the prevalence of current benzodiazepine use in methadone-maintenance treatment populations varies between 24.9% and 50.6%.<sup>
<xref ref-type="bibr" rid="bibr3-0960327111432503">3</xref>,<xref ref-type="bibr" rid="bibr4-0960327111432503">4</xref>
</sup> However, prevalence data suggest that most benzodiazepine users do not take illegal drugs.<sup>
<xref ref-type="bibr" rid="bibr4-0960327111432503">4</xref>
<xref ref-type="bibr" rid="bibr5-0960327111432503"/>–<xref ref-type="bibr" rid="bibr6-0960327111432503">6</xref>
</sup> In the study by Solhi et al., after a naloxone injection, 80%–100% of the patients, varying by type of benzodiazepine, significantly improved the main signs and symptoms such as lethargy, weakness, and ataxia, while there was no improvement in the control groups. It is unlikely that 80%–100% of the patients in this study were using illegal drug or synthetic opioids. In another word, there must be few, if not all, patients without any illegal drug or synthetic opioid use, whose symptoms and clinical signs were improved by naloxone, but not by control treatments.</p>
<p>Second, animal studies provide direct evidence that naloxone antagonizes gamma-aminobutyric acid (GABA)/benzodiazepine receptor functions. Electrophysiological data show that GABA-induced inhibition of neuronal firing in the brain of rat can be antagonized by naloxone.<sup>
<xref ref-type="bibr" rid="bibr7-0960327111432503">7</xref>
</sup> Furthermore, in experimental animals, naloxone antagonizes various benzodiazepine-induced behaviors, for example, hyperdipsia, hyperphagia, anticonflict effects, and anxiolytic-like effects.<sup>
<xref ref-type="bibr" rid="bibr8-0960327111432503">8</xref>
<xref ref-type="bibr" rid="bibr9-0960327111432503"/>
<xref ref-type="bibr" rid="bibr10-0960327111432503"/>–<xref ref-type="bibr" rid="bibr11-0960327111432503">11</xref>
</sup> These data suggest the direct interaction of naloxone with GABA/benzodiazepine receptor functions.</p>
<p>In summary, this study provides useful information on the treatment of benzodiazepine poisoning by naloxone. The nature of the mechanism involved, which needs further study, might involve its interaction with GABA receptors.</p>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327111432503">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327111432503">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solhi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mostafazadeh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Vishteh</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Ghezavati</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Shooshtarizadeh</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Benefit effect of naloxone in benzodiazepines intoxication: findings of a preliminary study</article-title>. <source>Hum Exp Toxicol</source> <year>2011</year>; <volume>30</volume>: <fpage>535</fpage>–<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr2-0960327111432503">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Tolchin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bruccoleri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>LS</given-names>
</name>
</person-group>. <article-title>Response to benefit effect of naloxone in benzodiazepines intoxication: findings of a preliminary study</article-title>. <source>Hum Exp Toxicol</source> <year>2011</year>; <volume>30</volume>: <fpage>343</fpage>.</citation>
</ref>
<ref id="bibr3-0960327111432503">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meiler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chatton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Broers</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Benzodiazepine use in a methadone maintenance programme: patient characteristics and the physician’s dilemma</article-title>. <source>Schweiz Arch Neurol Psychiatr</source> <year>2005</year>; <volume>156</volume>: <fpage>310</fpage>–<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr4-0960327111432503">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Forde</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>D’Adamo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gandhi</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Benzodiazepine use and misuse among patients in a methadone program</article-title>. <source>BMC Psychiatry</source> <year>2011</year>; <volume>11</volume>: <fpage>90</fpage>.</citation>
</ref>
<ref id="bibr5-0960327111432503">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gleason</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Newsom</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Kroboth</surname>
<given-names>PD,</given-names>
</name>
<name>
<surname>Kroboth</surname>
<given-names>FJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Correlates and prevalence of benzodiazepine use in community-dwelling elderly</article-title>. <source>J Gen Intern Med</source> <year>1998</year>; <volume>13</volume>: <fpage>243</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr6-0960327111432503">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parsells</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>AA</given-names>
</name>
</person-group>. <article-title>Prevalence and characteristics of opioid use in the US adult population</article-title>. <source>Pain</source> <year>2008</year>; <volume>138</volume>: <fpage>507</fpage>–<lpage>513</lpage>.</citation>
</ref>
<ref id="bibr7-0960327111432503">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dingledine</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Iversen</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Breuker</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies</article-title>. <source>Eur J Pharmacol</source> <year>1978</year>; <volume>47</volume>: <fpage>19</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr8-0960327111432503">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soubrié</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jobert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thiebot</surname>
<given-names>MH</given-names>
</name>
</person-group>. <article-title>Differential effects on naloxone against the diazepam-induced release of behavior in rats in three aversive situations</article-title>. <source>Psychopharmacology (Berl)</source> <year>1980</year>; <volume>69</volume>: <fpage>101</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr9-0960327111432503">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Effects of opiate antagonists and of morphine on chlordiazepoxide-induced hyperdipsia in the water-deprived rat</article-title>. <source>Neuropharmacology</source> <year>1982</year>; <volume>21</volume>: <fpage>1013</fpage>–<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr10-0960327111432503">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belzung</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Agmo</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Naloxone blocks anxiolytic-like effects of benzodiazepines in Swiss but not in Balb/c mice</article-title>. <source>Psychopharmacology (Berl)</source> <year>1997</year>; <volume>132</volume>: <fpage>195</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr11-0960327111432503">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agmo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Galvan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heredia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review</article-title>. <source>Psychopharmacology (Berl)</source> <year>1995</year>; <volume>120</volume>: <fpage>186</fpage>–<lpage>194</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>